Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 30 Sep 2021
Acacia Pharma announces submission and validation of marketing authorisation application for Barhemsys (amisulpride injection) in major European markets
29 September 2021 - Acacia Pharma announces that its marketing authorisation application for Barhemsys (amisulpride injection) has been submitted, validated and ...
Posted by Michael Wonder on 30 Sep 2021
Kesimpta: game changing multiple sclerosis drug now on PBS
30 September 2021 - A new drug that promises to change the lives of thousands of Australians living with multiple sclerosis ...
Posted by Michael Wonder on 30 Sep 2021
Landmark PBS listings to reduce the cost of medicines for Australians
30 September 2021 - From 1 October 2021, Australians with multiple sclerosis, multiple myeloma, macular degeneration and keratitis will have access ...
Posted by Michael Wonder on 30 Sep 2021
Prime Therapeutics and Pear Therapeutics announce first comprehensive value based agreement for prescription digital therapeutics reSET and reSET-O for the treatment of substance and opioid use disorders
29 September 2021 - Agreement aims to reduce inpatient hospitalisations and total cost of care. ...
Posted by Michael Wonder on 30 Sep 2021
Zogenix submits supplemental new drug application for Fintempla (fenfluramine) for the treatment of seizures associated with Lennox-Gastaut syndrome
28 September 2021 - Supplemental new drug application submission is supported by existing clinical data, including positive data from Company’s Phase ...
Posted by Michael Wonder on 29 Sep 2021
Data protection scheme for assessed listed medicines
29 September 2021 - The TGA has implemented a data protection scheme for assessed listed medicines. ...
Posted by Michael Wonder on 29 Sep 2021
Global disparity in access to novel therapeutics for metastatic prostate cancer
29 September 2021 - Access to androgen receptor directed therapies, which also have life-prolonging benefits in the castration-resistant prostate cancer ...
Posted by Michael Wonder on 29 Sep 2021
TransMedics receives FDA approval for its OCS Liver System for preservation and assessment of donor livers for transplantation
29 September 2021 - TransMedics today announced that the U.S. FDA has granted pre-market approval of its OCS Liver System ...
Posted by Michael Wonder on 29 Sep 2021
Benefit-risk assessment for new drug and biological products
29 September 2021 - The intent of this guidance is to clarify for drug sponsors and other stakeholders how considerations about ...
Posted by Michael Wonder on 29 Sep 2021
Helsinn Group and BridgeBio Pharma’s affiliate QED Therapeutics announce Health Canada conditional approval of Truseltiq (infigratinib) for patients with cholangiocarcinoma
29 September 2021 - Health Canada issues conditional approval of Truseltiq under Project Orbis (27 September 2021). ...
Posted by Michael Wonder on 29 Sep 2021
NuCana receives fast track designation from the U.S. Food and Drug Administration for Acelarin (NUC-1031) for the treatment of biliary tract cancer
29 September 2021 - NuCana announced that the U.S. FDA has granted fast track designation to Acelarin (NUC-1031), currently being evaluated ...
Posted by Michael Wonder on 29 Sep 2021
U.S. FDA approves Livmarli (maralixibat) as the first and only approved medication for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older
29 September 2021 - Mirum Pharmaceuticals today announced that the U.S. FDA has approved Livmarli (maralixibat) oral solution for the treatment ...
Posted by Michael Wonder on 29 Sep 2021
U.S. FDA accepts filings for Amicus’ AT-GAA for the treatment of Pompe disease
29 September 2021 - FDA sets PDUFA target action date of 29 May 2022 for the new drug application and 29 ...
Posted by Michael Wonder on 29 Sep 2021
EMA implements new measures to minimise animal testing during medicines development
29 September 2021 - EMA is putting in place special support to developers to replace, reduce and refine animal use for ...
Posted by Michael Wonder on 29 Sep 2021
Nonagen Bioscience granted FDA breakthrough device designation
28 September 2021 - Nonagen Bioscience today announced Oncuria, their non-invasive bladder cancer test capable of predicting response to therapy, has ...